The company is now unchanged by 0.00% since yesterday’s close of 3.70.

Castlight Health, Inc., launched on January 31, 2008, offers a health benefits platform that engages employees to make healthcare decisions, and enables employers to communicate and measure their benefit programs. The Company operates through cloud-based products segment. The Business’s technology offering aggregates data and applies analytics to make healthcare data transparent. Its products deliver employee engagement and enable employers to integrate benefit programs into a single platform available to employees and their families. The Business’s health benefits platform engages external data and its substantial user base to provide a single, end-to-end solution that integrates benefit programs and engages employees through personalized and relevant communications. Its offering provides employers the opportunity to communicate, measure, and get value out of their benefits and programs on a real-time basis. It obtains external data from a range of sources, such as healthcare providers, insurance companies, governmental agencies and quality-monitoring organizations, as well as internal data it generates from the usage of its products. It applies data science techniques, including predictive modeling and epidemiological analytics that engage its database to drive insights..

Advertisement

The most current P/E ratio is N/A and the market cap of the company is 494.83M. In the last earnings report the EPS was $-0.47 with 80.73M shares outstanding.

Investors are more bearish on Castlight Health Inc lately if you put credence in the increase in short interest. The company saw a rise in short interest from October 13, 2017 to October 31, 2017 of 1.21%. Short shares increased 56,709 over that timeframe. The days to cover decreased to 14.0 and the percentage of shorted shares was 0.06% on October 31.

Several ratings firms have provided guidance on the company. Chardan Capital lowered the price target of the stock on October 26 changing the forecast from $6.50 to $6.30 and stated a “Buy” rating. October 26 investment analysts at Canaccord Genuity left the company rating at “Buy” projecting a price of $7.00.

On October 25 Cantor Fitzgerald maintained a company rating of “Hold” with a current price target of $5.00.

On August 17, 2017 Dougherty & Co reiterated a “Buy” rating on the stock. August 3 investment analysts at Cowen and Company made no change to the company rating of “Market Perform” targeting a price of $4.50.